Caroline Hopkins

Articles Authored by Caroline Hopkins
MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Premium
If validated, the findings could inform strategies for improving responses to BRAF/MEK inhibitors including using androgen receptor blockers.

Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer
Premium
The firm envisions marketing the 53-gene signature with its existing MammaPrint and BluePrint tests as a comprehensive platform for breast cancer treatment selection.

Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals
Premium
The first test of its radiopharmaceutical technology will be in PSMA-positive prostate cancer, which is poised to enter the clinic later this year.

Biomarker-Defined Subset of Early Breast Cancer Patients Can Avoid Radiation, ASCO Data Show
The LUMINA trial showed that a molecularly defined subset of breast cancer patients over age 55 had an extremely low local recurrence rate when they omitted radiation.

With ASCO Data, Novartis' Tafinlar-Mekinist Heads Toward FDA for BRAF-Mutant Pediatric Brain Cancer
Premium
The targeted agents significantly improved response rates and survival times versus upfront chemotherapy for BRAF V600E-mutant pediatric low-grade glioma patients.

VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist
Premium
At ASCO, two sub-studies from the Phase III VISION trial shed light on which prostate cancer patients are likely to benefit most from Novartis' targeted radionuclide.

Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor
Researchers at ASCO shared data pointing to gene amplification, protein overexpression, and TP53 mutations as biomarkers for identifying best responders to adavosertib.

At ASCO, Biomarker Strategies Show Potential for Guiding Metastatic Pancreatic Cancer Treatment
Premium
Two studies presented Friday suggested that biomarker-selected approaches could improve patient outcomes on immunotherapy and targeted therapy.Â

Iovance Biotherapeutics Shares New TIL Data in Melanoma, Projects Lifileucel FDA Filing in August
Premium
Investors were unimpressed last week with the data they saw, though the company tried to reassure them that the findings were positive given the refractory population.

UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients
Premium
The study, conducted at the University of Southampton, homed in on crown-like structures of immune cells on the border of body fat and tumor tissue as a biomarker for anti-HER2 drug response.
